Top Tech Companies (766)
Don't see your company?
Create a company profile
BrightSpring is the parent company of a family of services and brands that provides clinical, nonclinical, pharmacy and ancillary care services for people of all ages, health and skill levels across home and community settings. The company is a leading provider of diversified home and community-based health and pharmacy services to medically complex and high-need populations. Its primary businesses include: behavioral health (including autism services), home health care (including personal care, home health, and hospice), neuro therapy, and job placement and vocational training, supported by pharmacy and telecare ancillary technologies and services. These businesses employ over 37,000 dedicated full-time equivalent team members in 50 states and provide services for over 350,000 people every day. BrightSpring is focused on providing quality outcomes and solutions through best-in-class services and investments in people, process and technology innovation, including the development of its Connected Home model of care. Founded and headquartered in Louisville, Kentucky, the company has been making a difference in communities since 1974 – helping people live their best life.
Developing next generation technologies for precision medicine and drug discovery
YonaLink provides EHR-to-EDC streaming and AI-driven CRF mapping to assist with clinical trial data management and improve trial efficiency and data quality.
.jpeg)
.png)
CyDex Pharmaceuticals is a pharmaceutical company that engages in the development and commercialization of drugs specifically designed.
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (Trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers, and is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. In 2020, G1 out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics. View our social community guidelines here: https://www.g1therapeutics.com/social-guidelines
Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of CNS diseases and disorders.
